Juventas Therapeutics Closes $22.2 Million Venture Capital Round

Juventas Therapeutics Closes $22.2 Million Venture Capital Round

07/16/2012

Cleveland, OH--Continuing its success in growing its strategic investor base, Juventas Therapeutics has closed a $22.2 million Series C venture capital investment that includes new investors Takeda Pharmaceuticals, Venture Investors, Tri-State Growth Fund, and Glengary Ventures. The round was led by previous investors Triathlon Medical Ventures and New Science Ventures, with participation from continuing investors Early Stage Partners, Fletcher Spaght Ventures, and Reservoir Venture Partners.
The funding will enable the company to simultaneously conduct two Phase II clinical trials, one for chronic heart failure and one for critical limb ischemia. Takeda's investment is financial only, with no special terms or strategic interests. Read more...


Find Out More About ESP

Staff Photo
Mike Bunker led the Early Stage Partners venture capital investment in Juventas Therapeutics